This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


4ia9

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "4ia9" [edit=sysop:move=sysop])
Current revision (15:18, 20 September 2023) (edit) (undo)
 
(6 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 4ia9 is ON HOLD
+
==Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzamide==
 +
<StructureSection load='4ia9' size='340' side='right'caption='[[4ia9]], [[Resolution|resolution]] 1.66&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[4ia9]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4IA9 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4IA9 FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.66&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=IA9:2-CHLORO-4-FLUORO-3-METHYL-N-[2-(4-METHYLPIPERAZIN-1-YL)-5-NITROPHENYL]BENZAMIDE'>IA9</scene>, <scene name='pdbligand=UNX:UNKNOWN+ATOM+OR+ION'>UNX</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ia9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ia9 OCA], [https://pdbe.org/4ia9 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ia9 RCSB], [https://www.ebi.ac.uk/pdbsum/4ia9 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ia9 ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/WDR5_HUMAN WDR5_HUMAN] Contributes to histone modification. May position the N-terminus of histone H3 for efficient trimethylation at 'Lys-4'. As part of the MLL1/MLL complex it is involved in methylation and dimethylation at 'Lys-4' of histone H3. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation. As part of the NSL complex it may be involved in acetylation of nucleosomal histone H4 on several lysine residues. May regulate osteoblasts differentiation.<ref>PMID:19556245</ref> <ref>PMID:19103755</ref> <ref>PMID:20018852</ref> <ref>PMID:16600877</ref> <ref>PMID:16829960</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
The WD40-repeat protein WDR5 plays a critical role in maintaining the integrity of MLL complexes and fully activating their methyltransferase function. MLL complexes, the trithorax-like family of SET1 methyltransferases, catalyze trimethylation of lysine 4 on histone 3, and they have been widely implicated in various cancers. Antagonism of WDR5 and MLL subunit interaction by small molecules has recently been presented as a practical way to inhibit activity of the MLL1 complex, and N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides were reported as potent and selective antagonists of such an interaction. Here, we describe the protein crystal structure guided optimization of prototypic compound 2 (K dis = 7 muM), leading to identification of more potent antagonist 47 (K dis = 0.3 muM).
-
Authors: DONG, A., DOMBROVSKI, L., BOLSHAN, Y., GETLIK, M., TEMPEL, W., KUZNETSOVA, E., WASNEY, G.A., HAJIAN, T., PODA, G., NGUYEN, K.T., SCHAPIRA, M., BROWN, P.J., Al-awar, R., Bountra, C., Arrowsmith, C.H., Edwards, A.M., SMIL, D., VEDADI, M., HONG, W., Structural Genomics Consortium (SGC)
+
Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction.,Bolshan Y, Getlik M, Kuznetsova E, Wasney GA, Hajian T, Poda G, Nguyen KT, Wu H, Dombrovski L, Dong A, Senisterra G, Schapira M, Arrowsmith CH, Brown PJ, Al-Awar R, Vedadi M, Smil D ACS Med Chem Lett. 2013 Feb 4;4(3):353-7. doi: 10.1021/ml300467n. eCollection, 2013 Mar 14. PMID:24900672<ref>PMID:24900672</ref>
-
Description: CRYSTAL STRUCTURE OF HUMAN WD REPEAT DOMAIN 5 WITH COMPOUND
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 4ia9" style="background-color:#fffaf0;"></div>
 +
 
 +
==See Also==
 +
*[[WD-repeat protein 3D structures|WD-repeat protein 3D structures]]
 +
== References ==
 +
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Homo sapiens]]
 +
[[Category: Large Structures]]
 +
[[Category: Al-awar R]]
 +
[[Category: Arrowsmith CH]]
 +
[[Category: Bolshan Y]]
 +
[[Category: Bountra C]]
 +
[[Category: Brown PJ]]
 +
[[Category: Dombrovski L]]
 +
[[Category: Dong A]]
 +
[[Category: Edwards AM]]
 +
[[Category: Getlik M]]
 +
[[Category: Hajian T]]
 +
[[Category: Kuznetsova E]]
 +
[[Category: Nguyen KT]]
 +
[[Category: Poda G]]
 +
[[Category: Schapira M]]
 +
[[Category: Smil D]]
 +
[[Category: Tempel W]]
 +
[[Category: Vedadi M]]
 +
[[Category: Wasney GA]]
 +
[[Category: Wu H]]

Current revision

Crystal structure of human WD REPEAT DOMAIN 5 in complex with 2-chloro-4-fluoro-3-methyl-N-[2-(4-methylpiperazin-1-yl)-5-nitrophenyl]benzamide

PDB ID 4ia9

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/4ia9"
Personal tools